|
WO2021072171A1
|
|
Cancer classification with tissue of origin thresholding
|
|
WO2021061473A1
|
|
Systems and methods for diagnosing a disease condition using on-target and off-target sequencing data
|
|
WO2021050439A1
|
|
Read-tier specific noise models for analyzing dna data
|
|
WO2021041840A1
|
|
Systems and methods for determining consensus base calls in nucleic acid sequencing
|
|
WO2021041968A1
|
|
Systems and methods for predicting and monitoring treatment response from cell-free nucleic acids
|
|
US2021065842A1
|
|
Systems and methods for determining tumor fraction
|
|
WO2020237184A1
|
|
Systems and methods for determining whether a subject has a cancer condition using transfer learning
|
|
US2020365229A1
|
|
Model-based featurization and classification
|
|
US2020340064A1
|
|
Systems and methods for tumor fraction estimation from small variants
|
|
US2020340063A1
|
|
Methylation-based false positive duplicate marking reduction
|
|
WO2020206041A1
|
|
Stratification of risk of virus associated cancers
|
|
US2020294624A1
|
|
Systems and methods for enriching for cancer-derived fragments using fragment size
|
|
WO2020163410A1
|
|
Detecting cancer, cancer tissue of origin, and/or a cancer cell type
|
|
WO2020163403A1
|
|
Detecting cancer, cancer tissue of origin, and/or a cancer cell type
|
|
WO2020154682A2
|
|
Detecting cancer, cancer tissue of origin, and/or a cancer cell type
|
|
US2020239965A1
|
|
Source of origin deconvolution based on methylation fragments in cell-free dna samples
|
|
WO2020132499A2
|
|
Systems and methods for using fragment lengths as a predictor of cancer
|
|
WO2020132544A1
|
|
Anomalous fragment detection and classification
|
|
WO2020132144A1
|
|
Methods for detecting disease using analysis of rna
|
|
US2020385813A1
|
|
Systems and methods for estimating cell source fractions using methylation information
|
